Stocks of Gossamer Bio Inc. (NASDAQ:GOSS) traded higher last session on Wall Street, up 2.46% to $1.25.
According to the data, Gossamer Bio Inc. (NASDAQ:GOSS) has 13 analysts covering its stock. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $15.00 and a low of $1.50, we find $5.50. Given the previous closing price of $1.22, this indicates a potential upside of 350.82 percent. GOSS stock price is now 1.32% away from the 50-day moving average and -77.52% away from the 200-day moving average. The market capitalization of the company currently stands at $112.03M.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
A total of 3 analysts have issued a hold rating and 9 have given it a buy rating. Brokers who have rated the stock have averaged $6.35 as their price target over the next twelve months.
In other news, Giraudo Bryan, COO/CFO bought 55,000 shares of the company’s stock on Apr 04. The stock was bought for $56,094 at an average price of $1.02. Upon completion of the transaction, the COO/CFO now directly owns 125,990 shares in the company, valued at $0.16 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 22, President & CEO Hasnain Faheem bought 440,500 shares of the business’s stock. A total of $503,580 was incurred on buying the stock at an average price of $1.14. This leaves the insider owning 4,495,897 shares of the company worth $5.62 million. Insiders disposed of 51,008 shares of company stock worth roughly $63760.0 over the past 1 year. A total of 1.20% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in GOSS stock. A new stake in Gossamer Bio Inc. shares was purchased by CITADEL ADVISORS LLC during the first quarter worth $3,493,000. PLATINUM INVESTMENT MANAGEMENT LTD invested $2,954,000 in shares of GOSS during the first quarter. In the first quarter, ERGOTELES LLC acquired a new stake in Gossamer Bio Inc. valued at approximately $2,165,000. HRT FINANCIAL LP acquired a new stake in GOSS for approximately $1,935,000. CENTIVA CAPITAL, LP purchased a new stake in GOSS valued at around $332,000 in the second quarter. In total, there are 175 active investors with 118.76% ownership of the company’s stock.
Tuesday’s opening bell rang with an opening price of $1.2100 for Gossamer Bio Inc. (NASDAQ: GOSS). During the past 12 months, Gossamer Bio Inc. has had a low of $0.91 and a high of $15.19. The fifty day moving average price for GOSS is $1.2349 and a two-hundred day moving average price translates $5.4959 for the stock.
The latest earnings results from Gossamer Bio Inc. (NASDAQ: GOSS) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$0.52, beating analysts’ expectations of -$0.53 by 0.01. This compares to -$0.76 EPS in the same period last year. The company reported revenue of $47.94 million for the quarter, compared to $54.34 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -11.78 percent.
Gossamer Bio Inc.(GOSS) Company Profile
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
